StreetInsider.com News Articles

Dogwood Therapeutics (DWTX) files for 4.1M share offering by selling stockholders

Fri, 30 Oct 2026 16:03:51 -0500

Dogwood Therapeutics (NASDAQ: DWTX) filed for up to 4,098,360 share offering by selling stockholders.

Dogwood Therapeutics (DWTX) files for 4.1M share offering by selling stockholders

Fri, 30 Oct 2026 16:03:51 -0500

Dogwood Therapeutics (NASDAQ: DWTX) filed for up to 4,098,360 share offering by selling stockholders.

Form S-3 Dogwood Therapeutics,

Fri, 30 Oct 2026 16:02:00 -0500

si-local-file:///var/storage/secattach/20261030/27266093.html

Form 4 Dogwood Therapeutics, For: Oct 26 Filed by: Conjoint Inc.

Tue, 27 Oct 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20261027/27241181.html

Form SCHEDULE 13D/A Dogwood Therapeutics, Filed by: Sealbond Ltd

Tue, 27 Oct 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20261027/27241167.html

Form SCHEDULE 13D/A Dogwood Therapeutics, Filed by: Sealbond Ltd

Wed, 21 Oct 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20261021/27216650.html

Form 8-K Dogwood Therapeutics, For: Oct 19

Mon, 19 Oct 2026 08:45:00 -0500

si-local-file:///var/storage/secattach/20261019/27201332.html

Dogwood Therapeutics raises $5M from largest shareholder

Mon, 19 Oct 2026 08:30:30 -0500

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced a $5 million private placement with a subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (HKEX: 0775), its largest shareholder, according to a press release dated Oct. 19, 2026.

Under the terms of the securities subscription agreement, Dogwood will issue 4,098,360 shares of common stock at $1.22 per share. The offering is priced at-the-market under Nasdaq rules and includes no warrants or other derivative securities. The transaction is expected to close on or before Oct. 29, 2026.

The company said it expects to use the proceeds to fund Phase 3 preparatory activities for its lead drug

Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.

Mon, 19 Oct 2026 08:30:00 -0500

- Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 -

- Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory Activities -

ATLANTA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that the Company has entered into a securities subscription agreement (the “Subscription Agreement”) for a $5 million investment from the Company’s largest shareholder, a subsidiary of CK

Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.

Mon, 19 Oct 2026 08:30:00 -0500

- Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 -

- Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory Activities -

Dogwood to Participate in the 2026 Maxim Growth Summit

Tue, 06 Oct 2026 08:45:00 -0500

ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that management will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12-14, 2026, in New York, NY. The conference brings together industry leaders, innovators, and investors to explore the latest trends and advancements across several industries.

Greg Duncan, Chief Executive Officer and Chairman of Dogwood, will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research

Dogwood to Participate in the 2026 Maxim Growth Summit

Tue, 06 Oct 2026 08:45:00 -0500

Greg Duncan, Chief Executive Officer and Chairman of Dogwood, will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research

Dogwood completes enrollment in Halneuron Phase 2b pain trial

Mon, 14 Sep 2026 08:45:14 -0500

Dogwood Therapeutics (Nasdaq: DWTX) announced the completion of patient enrollment in its Phase 2b clinical trial evaluating Halneuron® for chemotherapy-induced neuropathic pain (CINP), with topline data expected in November 2026.

The trial enrolled 239 patients, reaching the upper end of the company's planned enrollment target range. The randomized study compares Halneuron® against placebo in patients with moderate to severe neuropathic pain caused by prior platinum and/or taxane-based chemotherapy. Participants receive eight subcutaneous doses over 14 days and are followed for 28 days total.

The primary endpoint is the change from baseline to week four in the weekly average of daily 24-hour recall

Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial

Mon, 14 Sep 2026 08:45:00 -0500

- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range -

- Topline Data Expected in November 2026 -

ATLANTA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced the completion of patient enrollment in its ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathic Pain (“CINP”) trial. The Company anticipates topline data readout of the study in November 2026. Positive results from this study, if achieved, would represent

Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial

Mon, 14 Sep 2026 08:45:00 -0500

- Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range -

- Topline Data Expected in November 2026 -

H.C. Wainwright Reiterates Buy Rating on Dogwood Therapeutics, Inc. (DWTX)

Wed, 02 Sep 2026 07:08:17 -0500

H.C. Wainwright analyst Sean Lee reiterated a Buy rating and $12.00 price target on Dogwood Therapeutics, Inc. (NASDAQ: DWTX).

The analyst commented: "During the call, management disclosed that 232 patients have been recruited into the Phase 2b study of Halneuron for the treatment of CINP with the last patient to be randomized this week. They further reaffirmed the fall timing for the topline results, which we now expect between late-October to mid-November. Enrollment into the 12-week open label extension is now at 80+ patients, with 20 patients completing the 12 weeks of treatment. Early terminations from the extension study remain low

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026